Long-term survival of cancer patients compared to heart failure and stroke: a systematic review

Vasileios Askoxylakis, Christian Thieke, Sven T Pleger, Patrick Most, Judith Tanner, Katja Lindel, Hugo A Katus, Jürgen Debus, Marc Bischof, Vasileios Askoxylakis, Christian Thieke, Sven T Pleger, Patrick Most, Judith Tanner, Katja Lindel, Hugo A Katus, Jürgen Debus, Marc Bischof

Abstract

Background: Cancer, heart failure and stroke are among the most common causes of death worldwide. Investigation of the prognostic impact of each disease is important, especially for a better understanding of competing risks. Aim of this study is to provide an overview of long term survival of cancer, heart failure and stroke patients based on the results of large population- and hospital-based studies.

Methods: Records for our study were identified by searches of Medline via Pubmed. We focused on observed and relative age- and sex-adjusted 5-year survival rates for cancer in general and for the four most common malignancies in developed countries, i.e. lung, breast, prostate and colorectal cancer, as well as for heart failure and stroke.

Results: Twenty studies were identified and included for analysis. Five-year observed survival was about 43% for all cancer entities, 40-68% for stroke and 26-52% for heart failure. Five-year age and sex adjusted relative survival was 50-57% for all cancer entities, about 50% for stroke and about 62% for heart failure. In regard to the four most common malignancies in developed countries 5-year relative survival was 12-18% for lung cancer, 73-89% for breast cancer, 50-99% for prostate cancer and about 43-63% for colorectal cancer. Trend analysis revealed a survival improvement over the last decades.

Conclusions: The results indicate that long term survival and prognosis of cancer is not necessarily worse than that of heart failure and stroke. However, a comparison of the prognostic impact of the different diseases is limited, corroborating the necessity for further systematic investigation of competing risks.

Figures

Figure 1
Figure 1
Flow diagram of the study selection process.

References

    1. Yancik R. Population aging and cancer: a cross-national concern. Cancer J. 2005;11:437–41. doi: 10.1097/00130404-200511000-00002.
    1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–92. doi: 10.1093/annonc/mdl498.
    1. Kamangar F, Dores GM, Anderson WF. Pattern of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Clin Oncol. 2006;24:2137–50. doi: 10.1200/JCO.2005.05.2308.
    1. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O'Shaughnessy JA, Shen ZZ, Albain KS. ABREAST Investigators. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6:391–401. doi: 10.3816/CBC.2005.n.043.
    1. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology. 2009;73(Suppl 5):4–10. doi: 10.1016/j.urology.2009.03.001.
    1. Global cancer facts and figures 2007.
    1. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet. 2005;365:153–65. doi: 10.1016/S0140-6736(05)17706-X.
    1. Heart disease and stroke statistics-2007.
    1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:391–479. doi: 10.1161/CIRCULATIONAHA.109.192065.
    1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De SimoneG, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2010 update. A report from the American Heart Association. Circulation. 2010;121:46–215. doi: 10.1161/CIRCULATIONAHA.109.192703.
    1. Koelling TM, Chen RS, Lubwama RN, L'Italien GJ, Eagle KA. The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J. 2004;147:74–8. doi: 10.1016/j.ahj.2003.07.021.
    1. Warlow C. Epidemiology of stroke. Lancet. 1998;352(Suppl 3):1–4. doi: 10.1016/S0140-6736(98)90086-1.
    1. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet. 2003;362:1211–24. doi: 10.1016/S0140-6736(03)14544-8.
    1. Wolfe CD, Giroud M, Kolominsky-Rabas P, Dundas R, Lemesle M, Heuschmann P, Rudd A. for the European Registries of Stroke (EROS) Collaboration. Variations in stroke incidence and survival in 3 areas of Europe. Stroke. 2000;31:2074–2079.
    1. Brønnum-Hansen H, Davidsen M, Thorvaldsen P. Danish MONICA Study Group. Long-term survival and causes of death after stroke. Stroke. 2001;32:2131–6. doi: 10.1161/hs0901.094253.
    1. De Jong G, van Raak L, Kessels F, Lodder J. Stroke subtype and mortality: a follow-up study in 998 patients with first cerebral infarct. J Clin Epidemiol. 2003;56:262–8. doi: 10.1016/S0895-4356(02)00572-3.
    1. Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis. 2003;16(Suppl 1):14–19. doi: 10.1159/000069936.
    1. Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T. Survival of cancer patients in Europe: the EUROCARE Study. Lyon. IARC Scientific Publications No. 132; 1995.
    1. Berrino F, Capocaccia R, Estève J, Gatta G, Hakulinen T, Micheli A, Sant M, Verdecchia A. Survival of cancer patients in Europe: the EUROCARE-2 study. Lyon. IARC Scientific Publications No. 151; 1999.
    1. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hédelin G, Matsuda T, Møller H, Möller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D. EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. Ann Oncol. 2003;14(Suppl 5):61–118. doi: 10.1093/annonc/mdg754.
    1. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009;45:931–91. doi: 10.1016/j.ejca.2008.11.018.
    1. Gondos A, Holleczek B, Arndt V, Stegmaier C, Ziegler H, Brenner H. Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? Ann Oncol. 2007;18:1253–9. doi: 10.1093/annonc/mdm126.
    1. Gondos A, Arndt V, Holleczek B, Stegmaier C, Ziegler H, Brenner H. Cancer survival in Germany and the United States at the beginning of the 21st century: an up-to-date comparison by period analysis. Int J Cancer. 2007;121:395–400. doi: 10.1002/ijc.22683.
    1. Grivaux M, Zureik M, Marsal L, Asselain B, Peureux M, Chavaillon JM, Prud'homme A, Carbonnelle M, Goarant E, Maury B, Bedossa A, Blanchon F. Five year survival for lung cancer patients managed in general hospitals. Rev Mal Respir. 2009;26:37–44.
    1. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, E Silva GA, Francisci S, Santaquilani M, Verdecchia A, Storm HH, Young JL. CONCORD Working Group. Cancer survival in five continents: a worldwide population-based study (CONCORD) Lancet Oncol. 2008;9:730–56. doi: 10.1016/S1470-2045(08)70179-7.
    1. Meliker JR, Goovaerts P, Jacquez GM, Avruskin GA, Copeland G. Breast and prostate cancer survival in Michigan: can geographic analyses assist in understanding racial disparities? Cancer. 2009;115:2212–21. doi: 10.1002/cncr.24251.
    1. SEER cancer statistics review 1975-2005.
    1. Chia SE, Tan CS, Lim GH, Sim X, Pawitan Y, Reilly M, Mohamed Ali S, Lau W, Chia KS. Incidence, mortality and survival patterns of prostate cancer among residents in Singapore from 1968 to 2002. BMC Cancer. 2008;8:368. doi: 10.1186/1471-2407-8-368.
    1. Birgisson H, Talbäck M, Gunnarsson U, Påhlman L, Glimelius B. Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol. 2005;31:845–53. doi: 10.1016/j.ejso.2005.05.002.
    1. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JW, Capewell S, McMurray JJ. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119:515–23. doi: 10.1161/CIRCULATIONAHA.108.812172.
    1. Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12220 index admissions in Leicestershire 1993-2001. Heart. 2003;89:615–20. doi: 10.1136/heart.89.6.615.
    1. Mahjoub H, Rusinaru D, Soulière V, Durier C, Peltier M, Tribouilloy C. Long-term survival in patients older than 80 years hospitalised for heart failure. A 5-year prospective study. Eur J Heart Fail. 2008;10:78–84. doi: 10.1016/j.ejheart.2007.11.004.
    1. Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, Slama M, Massy Z. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J. 2008;29:339–47. doi: 10.1093/eurheartj/ehm554.
    1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9. doi: 10.1056/NEJMoa052256.
    1. Bravata DM, Ho SY, Brass LM, Concato J, Scinto J, Meehan TP. Long-term mortality in cerebrovascular disease. Stroke. 2003;34:699–704. doi: 10.1161/01.STR.0000057578.26828.78.
    1. Kim HC, Choi DP, Ahn SV, Nam CM, Suh I. Six-year survival and causes of death among stroke patients in Korea. Neuroepidemiology. 2009;32:94–100. doi: 10.1159/000177034.
    1. Reggiani M. Società Inter-Regionale Piemonte e Valle d'Aosta per le Cerebrovasculopatie Group. Five-year survival after first-ever ischaemic stroke is worse in total anterior circulation infarcts: The SINPAC Cohort. Cerebrovasc Dis. 2009;27:29–36. doi: 10.1159/000172631.
    1. Vernino S, Brown RD Jr, Sejvar JJ, Sicks JD, Petty GW, O'Fallon WM. Cause-specific mortality after first cerebral infarction: a population-based study. Stroke. 2003;34:1828–32. doi: 10.1161/01.STR.0000080534.98416.A0.
    1. Cheung CM, Tsoi TH, Hon SF, Au-Yeung M, Shiu KL, Lee CN, Huang CY. Outcomes after first-ever stroke. Hong Kong Med J. 2007;13:95–9.
    1. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year survival after first-ever stroke in the Perth Community Stroke Study. Stroke. 2003;34:1842–6. doi: 10.1161/.
    1. Hardie K, Jamrozik K, Hankey GJ, Broadhurst RJ, Anderson C. Trends in five-year survival and risk of recurrent stroke after first-ever stroke in the Perth Community Stroke Study. Cerebrovasc Dis. 2005;19:179–85. doi: 10.1159/000083253.
    1. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982;38:933–42. doi: 10.2307/2529873.
    1. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23:51–64. doi: 10.1002/sim.1597.
    1. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3:315–22. doi: 10.1016/S1388-9842(00)00141-0.
    1. Chiang CL. Competing risks in mortality analysis. Annu Rev Publ Health. 1991;12:281–307. doi: 10.1146/annurev.pu.12.050191.001433.
    1. Rothenberg RB. Competing mortality and progress against cancer. Epidemiology. 1994;5:197–203. doi: 10.1097/00001648-199403000-00010.
    1. Llorca J, Delgado-Rodríguez M. Competing risks analysis using Markov chains: impact of cerebrovascular and ischaemic heart disease in cancer mortality. Int J Epidemiol. 2001;30:99–101. doi: 10.1093/ije/30.1.99.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel